60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, showcasing its focus on developing new medicines for vector-borne diseases [1][2]. Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne diseases, with its lead product ARAKODA® (tafenoquine) approved by the U.S. FDA for malaria prevention in 2018 [3]. - ARAKODA is commercially available in the U.S. and Australia, and the company collaborates with prominent research and academic organizations in both countries [3]. Conference Details - Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals, will present live on September 10 at 2:30 ET, and management will conduct one-on-one meetings during the conference [2]. - Attendees can request meetings with management through the conference portal or directly with the company [2].